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fatty liver, alcoholic cirrhosis, chronic nonalcoholic liver disease,
viral hepatitis, and abnormal liver function tests. A multivariate
logistic regression was used to control for confounding variables.
RESULTS: A total of 5211 patients with schizophrenia were
identiﬁed, along with 20,844 controls. Patients were more likely
to be men than were controls (57.7% vs 26.2%, respectively, P
< 0.0001). No differences were observed in age (mean 43.1 vs.
42.8). The prevalence of liver diseases in patients with schizo-
phrenia (4.6%) was statistically signiﬁcantly higher than controls
(3.6%) after adjusting for age, gender and race (OR = 1.3,
[95%CI, 1.1–1.5], p = 0.0004). The rate was also higher than
the reported prevalence from the literature in the general popu-
lation (0.02%) [Psychosomatic Medicine 2006;68:684–691].
CONCLUSION: In this study, Medicaid recipients with schizo-
phrenia have a higher prevalence of liver diseases than Medicaid
recipients without clinically diagnosed mental illness, and also
have a higher prevalence of liver diseases than that reported for
the historical general population. The true prevalence may be
higher than that observed due to failure of asymptomatic cases
to present themselves. Clinicians should consider hepatic issues
in the management of their patients.
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MEASURING THE INFLUENCE OF MANAGED CARE ON
ANTIDEPRESSANT UTILIZATION BY CHILDREN AND
ADOLESCENTS WITH DEPRESSION
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OBJECTIVES: To assess the extent to which managed care
affects the utilization of antidepressants among commercially
insured children and adolescents diagnosed with depression.
METHODS: A sample of 5981 children and adolescents under
18 years of age with a diagnosis of depression was identiﬁed in
MedStats’s MarketScan database for 1997 and 1998. The like-
lihood of receiving an antidepressant was studied as a logistic
regression model that included structural, ﬁnancial, and personal
variables. A similar Cox regression analysis was conducted on a
subset of 1477 subjects who were new to therapy. RESULTS:
Personal variables with statistically signiﬁcant odds ratios
included: 1) use of other psychotropic drugs (exclusive of anti-
depressants), 2.50–3.15; 2) inpatient admission for psychiatric
condition 2.45–3.42; 3) chronic physical comorbidity 1.03–1.43;
4) parent(s) with diagnosis of depression 0.71–0.95; and, 5)
parental use of antidepressants 1.52–2.01. One structural vari-
able, membership in an EPO [exclusive provider network] rela-
tive to HMO, was associated with a greater likelihood of
antidepressant use, OR: 1.04–1.79. Structural variables that
reﬂected membership in various plan types were important when
assessing time to discontinuation. Variables with statistically 
signiﬁcant hazard ratios included: 1) membership in an EPO,
0.39–0.78, and 2) POS, 0.60–0.92. Personal variables reﬂecting:
1) use of other psychotropic drugs (exclusive of antidepressants),
0.72–0.91, and 2) age, 1.01–1.05 were also signiﬁcant. No ﬁnan-
cial variables (physician and pharmacy co-pay) or other struc-
tural variables (existence of a formularly and limits on mental
health outpatient visits) were signiﬁcant in either model. CON-
CLUSION: While personal factors can predict the use of anti-
depressants among children and adolescents with depression,
plan type may be more important in predicting length of therapy.
Membership in speciﬁc plan types, with different characteristics,
appears to affect the time to discontinuation of antidepressants
for commercially insured children and adolescents.
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OBJECTIVES: Our aim was to examine the relationship between
clinical indicators of disease activity in systemic lupus erythe-
matosus (SLE) and psychometrically derived and preference-
based measures of HRQL. METHODS: In a cross-sectional
study, patients with SLE completed 2 widely used generic HRQL
measures, EQ-5D and SF-36. Clinical measures included Sys-
temic Lupus Erythematosus Disease Activity Index (SLEDAI)
and physician global assessment. Known-groups comparisons
and correlations between clinical measure-based benchmarks
and HRQL scores were examined. RESULTS: There was a con-
sistent trend among patients with more disease activity (SLEDAI
score >6, n = 42/70) towards lower HRQL for all SF-36 domains
and HRQL summary scores (EQ-5D index, EQ-VAS, SF-6D).
Signiﬁcant differences in scores between low and high disease
activity were found for Role Physical (RP) [45(42) vs. 24(33)],
General Health (GH) [50(16) vs. 40(19)], SF-6D [0.66(0.12) vs.
59 (0.11)], EQ-VAS [78(18) vs. 62(20)] (all p-values <0.05).
SLEDAI was moderately correlated with MH (r = 0.32), SF-6D
(r = 0.33) and EQ-VAS (r = 0.43) (all p < 0.05), and weakly cor-
related (0.20 < r < 0.30) with PF, GH, and RP. Correlations
between physician global assessment and HRQL scores were
absent (r < 0.15) except for bodily pain (r = 0.30). CONCLU-
SION: While previous studies in SLE have reported little or no
correlation between measures of disease activity and SF-36
domain scores, results indicate that some generic HRQL mea-
sures, particularly the preference-based SF-6D and EQ-5D VAS,
demonstrated discriminative properties in patients with a range
of disease activity.
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OBJECTIVES: Disease-burden measured by preference-based
Health Related Quality of Life (HRQoL) scores is dependent on
the HRQoL instrument used. We test a simple mapping algo-
rithm to make disease-burden estimates across several HRQoL
scoring systems comparable. METHODS: We used National
Health Measurement Study (NHMS) data, a national sample of
3844 adults. We measured the burden associated with 31 health
conditions, as captured by 8 HRQoL instruments (EQ-5D with
UK and US scoring, HALex, HUI Mark 2 and Mark 3, QWB-
SA, SF-6D[12 and 36]) by regressing HRQoL scores onto each
condition, adjusting for age, sex, education, home ownership,
and race. The regression coefﬁcient for the health condition is
the “disease-burden”. We then regressed disease-burden mea-
sured by each HRQoL measure for the 31 conditions onto those
measured by the EQ-5D US. We test the resulting mapping algo-
rithms using 2000 Medical Expenditures Panel Survey (MEPS)
data (EQ-5D UK and SF-6D(12) to EQ-5D US) and US Valua-
tion of the EuroQol EQ-5D Health States (USVEQ) data (HUI
Mark2 and HUI Mark3 to EQ-5D US). RESULTS: Disease-
